UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

HACER: an atlas of human active enhancers to interpret regulatory variants

Nucleic acids research, 2019-01, Vol.47 (D1), p.D106

2019

Volltextzugriff (PDF)

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Cancer, 2017-11, Vol.123 (21), p.4099-4105

2017

Volltextzugriff (PDF)

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1666-1671

2019

Volltextzugriff (PDF)

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2015-05, Vol.10 (5), p.768-777

2015

Volltextzugriff (PDF)

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.876-889

2019

Volltextzugriff (PDF)

Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma

Journal of clinical oncology, 2013-12, Vol.31 (35), p.4387-4393

2013

Volltextzugriff (PDF)

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)

Clinical cancer research, 2018-03, Vol.24 (5), p.1038-1047

2018

Volltextzugriff (PDF)

Utilization and Influence of Online Support Communities in Idiopathic Subglottic Stenosis Patients

The Laryngoscope, 2021-08, Vol.131 (8), p.1821-1827

2021

Volltextzugriff (PDF)

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

The Journal of clinical investigation, 2023-01, Vol.133 (2), p.1-9

2023

Volltextzugriff (PDF)

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Journal of thoracic oncology, 2016-08, Vol.11 (8), p.1293-1304

2016

Volltextzugriff (PDF)

Scientific Rigor in the Age of COVID-19

JAMA oncology, 2021-02, Vol.7 (2), p.171

2021

Volltextzugriff (PDF)

Familial Aggregation in Idiopathic Subglottic Stenosis

Otolaryngology-head and neck surgery, 2020-11, Vol.163 (5), p.1011-1017

2020

Volltextzugriff (PDF)

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Cancer, 2016-03, Vol.122 (5), p.766-772

2016

Volltextzugriff (PDF)

Association between Estrogen Exposure and Idiopathic Subglottic Stenosis

The Laryngoscope, 2024-02, Vol.134 (2), p.825-830

2024

Volltextzugriff (PDF)

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Cancer, 2015-02, Vol.121 (3), p.448-456

2015

Volltextzugriff (PDF)

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

JAMA : the journal of the American Medical Association, 2014-05, Vol.311 (19), p.1998

2014

Volltextzugriff (PDF)

Characteristics of Lung Cancers Harboring NRAS Mutations

Clinical cancer research, 2013-05, Vol.19 (9), p.2584-2591

2013

Volltextzugriff (PDF)

Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial

BMJ open, 2018-04, Vol.8 (4), p.e022243-e022243

2018

Volltextzugriff (PDF)

Follow-up Interactive Long-Term Expert Ranking (FILTER): a crowdsourcing platform to adjudicate risk for survivorship care

JAMIA open, 2021-10, Vol.4 (4), p.ooab090-ooab090

2021

Volltextzugriff (PDF)

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100619-100619, Article 100619

2024

Volltextzugriff (PDF)

Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research

Gastroenterology (New York, N.Y. 1943), 2014-06, Vol.146 (7), p.1586-1590

2014

Volltextzugriff (PDF)

Isolation and characterization of a heavy metal- and antibiotic-tolerant novel bacterial strain from a contaminated culture plate of Chlamydomonas reinhardtii, a green micro-alga. [version 2; peer review: 2 approved]

F1000 research, 2021, Vol.10, p.533

2021

Volltextzugriff (PDF)

Isolation and characterization of a novel bacterial strain from a Tris-Acetate-Phosphate agar medium plate of the green micro-alga Chlamydomonas reinhardtii that can utilize common environmental pollutants as a carbon source

F1000 research, 2020, Vol.9, p.656

2020

Volltextzugriff (PDF)

Isolation and characterization of a novel Sphingobium yanoikuyae strain variant that uses biohazardous saturated hydrocarbons and aromatic compounds as sole carbon sources

F1000 research, 2020, Vol.9, p.767

2020

Volltextzugriff (PDF)

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11510-11510

2016

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(135)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

HACER: an atlas of human active enhancers to interpret regulatory variants

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)

Utilization and Influence of Online Support Communities in Idiopathic Subglottic Stenosis Patients

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Scientific Rigor in the Age of COVID-19

Familial Aggregation in Idiopathic Subglottic Stenosis

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Association between Estrogen Exposure and Idiopathic Subglottic Stenosis

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

Characteristics of Lung Cancers Harboring NRAS Mutations

Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial

Follow-up Interactive Long-Term Expert Ranking (FILTER): a crowdsourcing platform to adjudicate risk for survivorship care

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research

Isolation and characterization of a heavy metal- and antibiotic-tolerant novel bacterial strain from a contaminated culture plate of Chlamydomonas reinhardtii, a green micro-alga. [version 2; peer review: 2 approved]

Isolation and characterization of a novel bacterial strain from a Tris-Acetate-Phosphate agar medium plate of the green micro-alga Chlamydomonas reinhardtii that can utilize common environmental pollutants as a carbon source

Isolation and characterization of a novel Sphingobium yanoikuyae strain variant that uses biohazardous saturated hydrocarbons and aromatic compounds as sole carbon sources

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience

Suchergebnisse filtern